VRTX vs. BMRN

In the year-to-date period, VRTX achieves a 22.63% return, which is significantly higher than BMRN's -3.70% return. Over the past 10 years, VRTX has outperformed BMRN with an annualized return of 14.73%, while BMRN has yielded a comparatively lower -5.86% annualized return.

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

This table presents a comparison of risk-adjusted performance metrics for Vertex Pharmaceuticals Incorporated (VRTX) and BioMarin Pharmaceutical Inc. (BMRN). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

The current VRTX Sharpe Ratio is 0.84, which is higher than the BMRN Sharpe Ratio of -0.87. The chart below compares the historical Sharpe Ratios of VRTX and BMRN, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

Neither VRTX nor BMRN has paid dividends to shareholders.

The maximum VRTX drawdown since its inception was -91.77%, roughly equal to the maximum BMRN drawdown of -90.58%. Use the drawdown chart below to compare losses from any high point for VRTX and BMRN. For additional features, visit the drawdowns tool.

The current volatility for Vertex Pharmaceuticals Incorporated (VRTX) is 7.19%, while BioMarin Pharmaceutical Inc. (BMRN) has a volatility of 17.90%. This indicates that VRTX experiences smaller price fluctuations and is considered to be less risky than BMRN based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

This section allows you to compare key financial metrics between Vertex Pharmaceuticals Incorporated and BioMarin Pharmaceutical Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.